MicroRNAs in lung cancer

Diana Castro; Márcia Moreira; Alexandra Monteiro Gouveia; Daniel Humberto Pozza; Ramon Andrade De Mello

doi:10.18632/oncotarget.20955

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

MicroRNAs in lung cancer

Diana Castro, Márcia Moreira, Alexandra Monteiro Gouveia, Daniel Humberto Pozza and Ramon Andrade De Mello _

PDF | HTML | How to cite

Oncotarget. 2017; 8:81679-81685. https://doi.org/10.18632/oncotarget.20955

Metrics: PDF 1761 views | HTML 3504 views | ?

Abstract

Diana Castro1, Márcia Moreira1, Alexandra Monteiro Gouveia1,2,3, Daniel Humberto Pozza1,3 and Ramon Andrade De Mello4,5,6

1Department of Experimental Biology, Faculty of Medicine, University of Porto, Porto, Portugal

2Institute for Cellular and Molecular Biology (IBMC), Institute for Health Innovation, University of Porto, Porto, Portugal

3Faculty of Nutrition and Food Sciences, University of Porto, Porto, Portugal

4Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal

5Department of Medicine, Faculty of Medicine, University of Porto, Porto, Portugal

6Cearense School of Oncology, Ceará Cancer Institute, Fortaleza, Brazil

Correspondence to:

Ramon Andrade De Mello, email: [email protected]

Keywords: microRNAs, lung cancer, inflammation, epithelial mesenchymal transition, interleukin 1

Received: April 12, 2017 Accepted: August 26, 2017 Published: September 16, 2017

ABSTRACT

Lung cancer (LC) is a serious public health problem responsible for the majority of cancer deaths and comorbidities in developed countries. Tobacco smoking is considered the main risk factor for LC; however, only a few smokers will be affected by this cancer. Current screening methods are focused on identifying the early stages of this malignancy. Thus, new data concerning the roles of microRNA alterations in inflammation, epithelial-mesenchymal transition and lung disease have increased hope about LC pathogenesis, diagnosis, treatment and prognosis. MicroRNA mechanisms include angiogenesis promotion, cell cycle regulation by modulating cellular proliferation and apoptosis, and migration and invasion inhibition. In this context, this manuscript reviews the current information about many important microRNAs as they relate to the initiation and progression of LC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20955

Publication Alerts

Reviews:

MicroRNAs in lung cancer

Abstract